Blue Ocean Technologies & FlexTrade Systems Announce Connectivity Partnership
FlexTrade Systems (@FlexTrade), a global leader in high-performance multi-asset sell-side technology and Blue Ocean Technologies (BOT), a unique capital markets fintech leader in global afterhours trading, announced today a connectivity partnership to broaden access to FlexTrade’s sell-side order management solutions for broker-dealer subscribers. As part of the partnership, FlexTrade is offering broker-dealer clients access to the Blue Ocean ATS trading platform for after–hours trading in US equities from 8:00 pm – 4:00 am EST, further driving development within the 24-hour global equities trading sector.
Brian Hyndman, President and CEO of Blue Ocean Technologies and Blue Ocean ATS, commented, “We are delighted to partner with a respected industry leader such as FlexTrade. Blue Ocean Technologies average daily volume has grown 230% in 2023 from 2022, validating the overall need for the offering providing additional choices for investors that want to manage their risk., validating the overall need for the offering providing additional choices for investors that want to manage their risk. The expansion is due in large part to connectivity partnerships with trading platforms like FlexTrade Systems. With this newest partnership, FlexTrade is providing users with access to our Blue Ocean Sessions service, underscoring the importance of providing users with new routing choices, more trading flexibility, and transparency after hours. We are excited to continue growing our reach for traders globally,” he added.
FlexTrade Systems’ Shane Remolina, Director of Business Development, Sell-Side Trading Solutions added, “FlexTrade’s objectives include providing best-in-class service and support coupled with cutting-edge feature sets and functionality to our clients. Partnering with Blue Ocean is a natural fit and next step that will enable clients with large trading flows in the APAC region to access Blue Ocean’s overnight session in US names. We are extremely excited to have added Blue Ocean connectivity to FlexTrade’s already best-in-class institutional grade retail trading suite.”
About Blue Ocean Technologies:
Blue Ocean Technologies, LLC (BOT) is a unique capital markets fintech company empowering global investors by making trading possible during US overnight trading hours. Blue Ocean Technologies’ US broker dealer subsidiary, Blue Ocean ATS, LLC, and its trading system Blue Ocean Alternative Trading System (BOATS), currently trade US National Market System (NMS) stocks from 8:00 pm to 4:00 am ET from Sunday – Thursday. Founded in 2019, Blue Ocean ATS is on a mission to transform US trading to Global trading via its flagship service, Blue Ocean Session, providing access and transparency to subscribers in all time zones during non-traditional US market hours. Learn more about how to connect to: sales@blueoceanats. For additional information, please visit our website: www.blueocean-tech.io and follow us on LinkedIn and Twitter.
About FlexTrade Systems Sell-Side Trading Solutions:
FlexTrade Systems is a global financial technology firm that aims to boost trading efficiency by simplifying the complexities of today’s trading workflows through the provision of a unified multi-asset sell-side trading platform. Recognizing its mission-critical role, FlexTrade achieves this goal with unparalleled service and support for high touch and low touch businesses across cash, program trading, futures & options, ETF, swaps, and foreign exchange workflows. Whether the focus is on a market-making, agency, retail, or, proprietary trading desk, FlexTrade can enhance a broker-dealers complete order management lifecycle from order receipt, and trading, to middle and back-office workflows, in a single, technology platform.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005376/en/
Contact information
Blue Ocean Technologies
press@blueocean-tech.io
FlexTrade Systems
Matthew Halicki
Vice President, Marketing
matthew.halicki@flextrade.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 01:13:00 EET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release
SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom